AllianceXPartners

US lawmakers have advanced appropriations language that would bar the FDA from accepting clinical trial data generated at sites in Russia, China, Iran or North Korea. For any organization running trials across EAEU markets — where Russia is the largest single market — this is a design constraint, not a footnote.

Every trial AllianceXPartners structures is built as a two-track, multi-regional protocol from day one. The FDA track runs across the United States, the EU/ICH region, and non-restricted EAEU states — Uzbekistan, Kazakhstan, Armenia and Kyrgyzstan. A separate EAEU registration track, run in Russia and Belarus, supports local registration and post-marketing study only, and never enters the FDA data package. One protocol, two compliant tracks, no ambiguity about which data goes where.

Full detail on our clinical network and site footprint, including our sanctions posture on fund and data flows, is on the Clinical Trial Network page.